Overview
The marketing authorisation for Zurampic has been withdrawn at the request of the marketing-authorisation holder.
Zurampic : EPAR - Summary for the public
Zurampic : EPAR - Risk-management-plan summary
Product information
Zurampic : EPAR - Product Information
Latest procedure affecting product information: IA/0008
15/06/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zurampic : EPAR - All Authorised presentations
Product details
- Name of medicine
- Zurampic
- Active substance
- lesinurad
- International non-proprietary name (INN) or common name
- lesinurad
- Therapeutic area (MeSH)
- Hyperuricemia
- Anatomical therapeutic chemical (ATC) code
- M04AB05
Pharmacotherapeutic group
Antigout preparationsTherapeutic indication
Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
Assessment history
Zurampic : EPAR - Procedural steps taken and scientific information after authorisation